However, extending trametinib use in neuroblastoma is challenged by the fact that constitutively active YAP overexpression induces resistance against trametinib in MAPK pathway-activated neuroblastoma cells via transcriptional activation of E2F and MYCN [79]. This evidence concerns the gene MYCN and neuroblastoma.